guidelines on acute pe 2014 (tf03) - tf members · 2015-01-29 · - stealth peptides : bendavia...

Agnelli Giancarlo A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Bayer Healthcare : rivaroxaban (2011-2012)

- Pfizer : apixaban (2012-2013-2014)

- Bristol Myers Squibb : apixaban (2012-2013-2014)

- Boehringer-Ingelheim : dabigatran (2012-2013-2014)

- Bayer AG : rivaroxaban (2013-2014)

D - Research funding (departmental or institutional).- Bayer Healthcare : rivaroxaban (2011)

Danchin Nicolas A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Servier : antianginal agents (2011-2012-2013-2014)

- Boehringer-Ingelheim : Antithrombotic agents (2011-2012-2013-2014)

- BMS/Pfizer : Antithrombotic agents (2011-2012-2013-2014)

- Medicines Company : Antithrombotic agents (2011-2012-2013-2014)

- Daiichi Sankyo, Eli-Lilly : Antithrombotic agents (2011-2012-2013-2014)

- Sanofi Aventis : antithrombotic agents, antiarrhythmic agents (2011-2012-2013-2014)

- Astra Zeneca : Antithrombotic agents, statins (2011-2012-2013-2014)

- Roche Pharma : Dalcetrapib (2011-2012-2013-2014)

- Novo-Nordisk : Diabetes (2011-2012-2013-2014)

- Pierre-Fabre : Omega 3 (2011-2012-2013-2014)

- Bayer : Rivaroxaban (2012-2013-2014)

- Amgen : Lipid lowering drugs (2013-2014)

D - Research funding (departmental or institutional).- Astra Zeneca : Myocardial infarction (2011-2012-2013-2014)

- Sanofi Aventis : Myocardial infarction (2011-2012-2013-2014)

22/08/2014

Guidelines on Acute PE 2014 (TF03) - TF Members

Expert Type of Relationship with Industry

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

of 43

Danchin Nicolas - GlaxoSmithKline : Myocardial infarction (2011-2012-2013-2014)

- Medicines Company : Myocardial infarction (2011-2012-2013-2014)

- Merck Sharp & Dohme : Myocardial infarction (2011-2012-2013-2014)

- Daiichi-Sankyo Eli Lilly : Myocardial infarction (2011-2012-2013-2014)

Fitzmaurice David A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Roche Diagnostics : Anticoagulation (2011-2012-2013-2014)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Boehringer-Ingelheim : Anticoagulation (2011-2012-2013-2014)

D - Research funding (departmental or institutional).- Leo Pharma : Deep Vein Thrombosis (2011-2012-2013-2014)

Galie Nazzareno A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- GlaxoSmithKline : ambrisentan (2011)

- Actelion : bosentan, macitentan, selexipag (2011)

- Lilly : tadalafil (2011)

- Bayer Healthcare : riociguat (2011-2014)

- Pfizer : sildenafil (2011-2014)

- Eli Lilly : pulmonary hypertension (2012-2013)

- Novartis : pulmonary hypertension (2012-2013)

- Pfizer : pulmonary hypertension (2012-2013)

- Actelion : pulmonary hypertension (2012-2013)

- GlaxoSmithKline : pulmonary hypertension (2012-2013)

- Bayer AG : pulmonary hypertension (2012-2013)

- GSK : Ambrisentan and Tadalafil (2014)

- Actelion : macitentan (2014)

22/08/2014




of 43

Galie Nazzareno D - Research funding (departmental or institutional).- GlaxoSmithKline : ambrisentan (2011)

- Actelion : selexipag (2011-2014)


- Pfizer : pulmonary hypertension (2012-2013)

- Actelion : pulmonary hypertension (2012-2013)

- GlaxoSmithKline : pulmonary hypertension (2012-2013)

- Bayer AG : pulmonary hypertension (2012-2013)

- GSK : ambrisentan and Tadalafil (2014)

- Bayer Healthcare : riociguat (2014)

Gibbs Simon A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Actelion : Pulmonary hypertension: bosentan (2011)

- GlaxoSmithKline : Pulmonary hypertension: ambrisentan, Flolan (2011-2012)

- Lilly : Pulmonary hypertension: Tadalafil (2011-2012)

- United Therapeutics : Pulmonary hypertension: Treprostinil (2011-2012)

- Novartis : Trial adjudication Committee member (2011-2012-2013-2014)

- Pfizer : Pulmonary hypertension: Sildenafil (2011-2012-2014)

- Actelion : Pulmonary hypertension: bosentan, macitentan (2012)

- Bayer AG : Pulmonary hypertension: riociguat (2012-2014)

- Gilead : Trial Adjudication Committee member (2012-2014)

- AOP Orphan Pharmaceuticals : Pulmonary hypertension (2013)

- Actelion : Pulmonary hypertension: bosentan, macitentan; Trial adjudication Committee member (2013)

- GlaxoSmithKline : Pulmonary hypertension: ambrisentan, epoprostenol (2013-2014)

22/08/2014




of 43

Gibbs Simon - Actelion : Pulmonary hypertension: bosentan, macitentan; epoprostenol (2014)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Gilead : Ambrisentan (2011)

D - Research funding (departmental or institutional).- United Therapeutics : Pulmonary hypertension: treprostinil (2011-2012)

Huisman Menno A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Boehringer-Ingelheim : thrombosis (2011)

- Pfizer : thrombosis (2011)

- Bayer Healthcare : thrombosis (2011)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- GlaxoSmithKline : thrombosis (2011-2014)

- Bristol Myers Squibb : thrombosis (2013)

- Boehringer-Ingelheim : thrombosis (2013-2014)

D - Research funding (departmental or institutional).- GlaxoSmithKline : thrombosis (2012-2013)

- Boehringer-Ingelheim : thrombosis (2012-2013-2014)

E - Research funding (personal).- Boehringer-Ingelheim : thrombosis (2011)

- GlaxoSmithKline : thrombosis (2011-2014)

Humbert Marc A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- United Therapeutics : Pulmonary Hypertension (2011)

- Bayer : Pulmonary Hypertension (2011-2012-2013-2014)

- Novartis : Pulmonary Hypertension (2011-2012-2013-2014)

- Pfizer : Pulmonary Hypertension (2011-2012-2013-2014)

- Actelion : Pulmonary Hypertension (2011-2012-2013-2014)

- GlaxoSmithKline : Pulmonary Hypertension (2011-2012-2013-2014)

22/08/2014




of 43

Humbert Marc - Lilly : Pulmonary Hypertension (2011-2012-2013-2014)

- Aires : Pulmonary Hypertension (2012-2013-2014)

D - Research funding (departmental or institutional).- Bayer : Pulmonary Hypertension (2011-2012-2013-2014)

- Pfizer : Pulmonary Hypertension (2011-2012-2013-2014)

- Actelion : Pulmonary Hypertension (2011-2012-2013-2014)

- GlaxoSmithKline : Pulmonary Hypertension (2011-2012-2013-2014)

Konstantinides Stavros V A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Servier : Antianginal drugs (unrelated to venous thromboembolism) (2011)

- Astra Zeneca : Antiplatelet agents (unrelated to venous thromboembolism) (2011)

- Boehringer-Ingelheim : New oral anticoagulant drugs (2011)

- Bayer Healthcare : New oral anticoagulant drugs (2011)

- Bristol Myers Squibb : Anticoagulant drugs: Apixaban (2012)

- Boehringer-Ingelheim : Anticoagulant drugs: dabigatran (2012)

- Daiichi Sankyo : Anticoagulant drugs: Edoxaban (2012)

- Bayer Healthcare : Anticoagulant drugs: rivaroxaban (2012)

- Servier : Ivabradine (2012)

- Astra Zeneca : Ticagrelor (2012)

- Boehringer-Ingelheim : Anticoagulation (2013-2014)

- Daiichi Sankyo : Anticoagulation (2013-2014)

- Bristol Myers Squibb : Anticoagulation (2013-2014)

- Bayer Healthcare : Anticoagulation; pulmonary hypertension (2013-2014)

- Astra Zeneca : Antiplatelet agents (2013-2014)

22/08/2014




of 43

Konstantinides Stavros V - Servier : Heart failure (2013-2014)

D - Research funding (departmental or institutional).- Bayer Healthcare : Anticoagulation (investigator initiated trials) (2013-2014)

Kucher Nils A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- EKOS Corp : EkoSonic Mach 4 catheter (2011-2012-2013-2014)

- Sanofi-Aventis : Enoxaparin (2011-2012-2013-2014)

- Bayer Healthcare : Rivaroxaban, AngioJet (2011-2012-2013-2014)

- Straub Medical : Aspirex thrombectomy (2014)

- Promedics : Vein stents (2014)

D - Research funding (departmental or institutional).- EKOS Corp : Management of VTE (2011-2012)

- Bayer Healthcare : Management of VTE (2011-2012-2013-2014)

- Bristol Myers Squibb : Management of VTE (2011-2012-2013-2014)

- Sanofi-Aventis : Management of VTE (2011-2012-2013-2014)

- Pfizer : Manegement of VTE (2011-2012-2013-2014)

Lang Irene Marthe A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Cordis : Cypher (2011-2012-2013)

- Spectranetics : Laser (2011-2012-2013)

- Boston Scientific : stents (2011-2012-2013)

- Lilly : Tadalafil, ReoPro (2011-2012-2013)

- Merck Sharp & Dohme : Vernakalant (2011-2012-2013)

- GlaxoSmithKline : Ambrisentan (2011-2012-2013-2014)

- Actelion : Bosentan (2011-2012-2013-2014)

- Boehringer-Ingelheim : Dabigatran (2011-2012-2013-2014)

22/08/2014




of 43

Lang Irene Marthe - Servier : Procoralan (2011-2012-2013-2014)

- Medtronic : Resolute (2011-2012-2013-2014)

- Bayer Healthcare : Riociguat (2011-2012-2013-2014)

- Astra Zeneca : Rosiglitazone (2011-2012-2013-2014)

- Biotronik : stents (2011-2012-2013-2014)

- United Therapeutics : Treprostinil (2011-2012-2013-2014)

- Cordis : Vista BriteTip (2014)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Servier : Clarify Registry (2012-2013-2014)

D - Research funding (departmental or institutional).- Actelion : Bosentan (2011-2012-2013-2014)

Lankeit Mareike A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Pfizer : Apixaban (2012)

- Bayer Healthcare : Rivaroxaban, venous thromboembolism, chronic thromboembolic pulmonary hypertension (2012)

- Pfizer : Apixaban, venous thromboembolism (2013)

- Bayer Healthcare : Rivaroxaban, riociguat, venous thromboembolism, chronic thromboembolic pulmonary hypertension (2013-2014)

- Pfizer/BMS : apixaban, venous thromboembolism (2014)

E - Research funding (personal).- German Cardiac Society : Fellowship (50,000€ once), Project titel: „Laboratory biomarkers, alone or in combination with

clinical scores, for the identification of patients with low-risk acute pulmonary embolism“ (2011)

Lekakis John A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Actelion : Pulmonary hypertension (2011)

- Astra Zeneca : Hyperlipidemia (2011-2013)

- Pfizer : Congestive heart failure (2012)

- GlaxoSmithKline : Darapladib (2012)

22/08/2014




of 43

Lekakis John - Bayer : Rivaroxaban (2012-2014)

- Pfizer : HEART FAILURE (2013)

- Menarini : RANOLAZINE (2014)

- Astra Zeneca : ROSUVASTATIN (2014)

Maack Christoph None declared (2011)

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Pfizer : Eplerenone (2012)

- Berlin Chemie AG : Ranolazine (2012-2013-2014)

- Stealth Peptides : Bendavia (2013-2014)

- Pfizer : Eplerenone, Apixaban (2013-2014)

- Deutsche Hypertonie Akademie : Hypertension and heart failure (2013-2014)

- Servier : Ivabradine (2013-2014)

- Bayer AG : Rivaroxaban (2013-2014)

C - Receipt of royalties for intellectual property.- Deutsche Hypertonie Akademie : Hypertension and heart failure (2012)

Mayer Eckhard A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Bayer Schering Pharma : Pulmonary Hypertension (2011)

- Pfizer : pulmonary hypertension (2012-2013-2014)

- Actelion : pulmonary hypertension (2012-2013-2014)

- GlaxoSmithKline : pulmonary hypertension (2012-2013-2014)

- Bayer Healthcare : pulmonary hypertension (2012-2013-2014)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Pfizer : Pulmonary Hypertension (2011)

- Bayer Healthcare : CTEPH (2013-2014)

22/08/2014




of 43

Mayer Eckhard C - Receipt of royalties for intellectual property.- Actelion : Pulmonary Hypertension (2011)

Meneveau Nicolas A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Lilly : Prasugrel, abciximab (2011-2012)

- Astra Zeneca : Ticagrelor (2011-2012)

- Boehringer-Ingelheim : Dabigatran (2011-2012-2013)

- saint Jude medical : Consultant (OCT, FFR) (2011-2012-2013-2014)

- GlaxoSmithKline : Fondaparinux (2012)

- BMS/Pfizer : Apixaban (2012-2013-2014)

- Bayer Healthcare : Rivaroxaban (2012-2013-2014)

- Daiichi Sankyo : Edoxaban (2013)

- Abbott Vascular : Stent Absorb (2014)

- Edwards Life Sciences : TAVI (2014)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- BMS/Pfizer : Apixaban (AMPLIFY Study) (2011-2012)

- Daiichi Sankyo : Edoxaban (HOKUSAÏ study) (2011-2012)

- Bayer : Rivaroxaban (EINSTEIN PE study) (2011-2012)

- Astra Zeneca : Ticagrelor (2013)

D - Research funding (departmental or institutional).- Boehringer-Ingelheim : dabigatran (2014)

- Abott vascular : DES (2014)

- Bayer Healthcare : rivaroxaban (2014)

Perrier Arnaud None declared (2011-2012-2013-2014)

Pruszczyk Piotr A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Servier : hypertension (2011)

22/08/2014




of 43

Pruszczyk Piotr - Boehringer-Ingelheim : anticoagulation in AF (2011-2012)

- Bayer Healthcare : anticoagulation in AF (2011-2012)

- Sanofi Aventis : anticoagulation (2011-2012-2013-2014)

- Pfizer : anticagulation (2012-2013-2014)

- Boehringer-Ingelheim : anticoagulation (2013-2014)

- Bayer Healthcare : anticoagulation (2013-2014)

Rasmussen Lars Hvilsted A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astra Zeneca : Cardiology (2011)

- Bayer : Cardiology (2011)

- Boehringer-Ingelheim : Cardiology (2011)

- Pfizer : Cardiology (2011)

- Heart.org : Cardiology (2011)

- Nycomed : Cardiology (2011)

- Bristol Myers Squibb : Cardiology (2011)

- Boehringer-Ingelheim : Atrial fibrillation (2012)

- Pfizer : Atrial fibrillation (2012)

- Bristol Myers Squibb : Atrial fibrillation (2012)

- Bayer : Atrial fibrillation (2012-2013)

- Bayer : Atrial fibrilation and thrombosis (2014)

- Boehringer-Ingelheim : Atrial fibrilation and thrombosis (2014)

- Pfizer : Atrial fibrilation and thrombosis (2014)

- Bristol Myers Squibb : Atrial fibrilation and thrombosis (2014)

- Roche Diagnostics : Atrial fibrilation and thrombosis (2014)

22/08/2014




of 43

Rasmussen Lars Hvilsted B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Boehringer-Ingelheim : Atrial Fibrillation (2013)

- Daiichi Sankyo : Atrial fibrilation and thrombosis (2014)

C - Receipt of royalties for intellectual property.- Bristol Myers Squibb : Atrial Fibrillation (2013)

D - Research funding (departmental or institutional).- Daiichi Sankyo : Atrial Fibrillation (2013)

- Roche Diagnostics : Atrial Fibrillation (2013)

E - Research funding (personal).- Pfizer : Atrial fibrillation (2013)

Schindler Thomas Hellmut None declared (2011-2012-2014)

E - Research funding (personal).- John's Hopkins University : Cardiovascular research (2013)

Svitil Pavel None declared (2011)

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Bayer AG : Apixaban (2012)

- Zentiva : Hypercholesteroaemia (2012)

- Abbott : Hypertension treatment (2012)

- Astra Zeneca : Ticargrelor (2013-2014)

Torbicki Adam A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Actelion : pulmonary arterial hypertension - macisentan, selexipag (2011)

- Bayer Healthcare : pulmonary arterial hypertention - iloprost, riociguat (2011)

- United Therapeutics : Pulmonary arterial hypertension (2011-2012)

- Lilly : pulmonary arterial hypertension - tadalafil (2011-2012)

- AOP Orphan Pharmaceuticals : Pulmonary arterial hypertension - treprostinil (2011-2012)

- Bristol Myers Squibb : thromboembolic disease - Apixaban (2011-2012)

22/08/2014




of 43

Torbicki Adam - GlaxoSmithKline : pulmonary arterial hypertension - ambrisentan (2011-2012-2013)

- Cardiomems : implanted pulmonary artery pressure sensor (2012)

- Actelion : pulmonary arterial hypertension - macitentan, selexipag (2012-2013-2014)

- Bayer Healthcare : pulmonary arterial hypertention - iloprost, riociguat, VTE - xarelto (2012-2013-2014)

- Bristol Myers Squibb : Pulmonary arterial hypertension (2013)

- Lilly : pulmonary arterial hypertension - ambrisentan (2013)

- Novartis : pulmonary hypertension (2014)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Sanofi Aventis : Thromboembolic disease (2011-2012)

- Bayer Healthcare : Pulmonary hypertension (2011-2012-2013-2014)

Vonk Noordegraaf Antonie A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- United Therapeutics : remodulin (2011-2012-2013-2014)

- Pfizer : Revatio (2011-2012-2013-2014)

- Bayer Schering Pharma : ricociguat (2011-2012-2013-2014)

- Lilly : tardanafil (2011-2012-2013-2014)

- Actelion : tracleer (2011-2012-2013-2014)

- GlaxoSmithKline : Volibris (2011-2012-2013-2014)

Zamorano Gomez Jose Luis

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Abbott Vascular : Help in Design Echocardiographic protocol (2012)

- Merck Sharp & Dohme : Lecture (2012)

- Daiichii : Atrial Fib (2013)

- Merck Sharp & Dohme : Lipid Lowering (2013)

- Philips : 3D echo (2014)

- MSD : CV risk factors (2014)

22/08/2014




of 43


- Toshiba medical imaging : fusion imaging 3D echo CT (2014)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Abbott Vascular : IMAGING IN HF (2011)

- Merck Sharp & Dohme : LIPIDS (2011)

- European Research Foundation FP7 : CV Imaging (2012)

- European Research FP7 : CV Imaging (2013)

- Servier : Imaging in ISchemic patients (2013)

- Siemens Healthcare : 3d echo software and free style echo (2014)

C - Receipt of royalties for intellectual property.- Springer : ESC Textbook of CV Imaging (2012-2013)

D - Research funding (departmental or institutional).- Astra Zeneca : Clinical trial (2014)

- Ikaria : Clinical trial (2014)

Zompatori Maurizio None declared (2011-2012-2013-2014)

22/08/2014




of 43

Ag Baccar Hedi A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Pfizer : advisory board NOAC (2012-2013-2014)

Ageno Walter A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Stago : Anticoagulant therapies (2012)

- GlaxoSmithKline : Anticoagulant therapies (2012-2013)

- Boehringer-Ingelheim : Anticoagulant therapies (2012-2013-2014)

- Daiichi Sankyo : Anticoagulant therapies (2012-2013-2014)

- Pfizer : Anticoagulant therapies (2012-2013-2014)

- Bayer Healthcare : Anticoagulant therapies (2012-2013-2014)

- Bristol Myers Squibb : Anticoagulant therapies (2012-2013-2014)

D - Research funding (departmental or institutional).- Bayer Healthcare : Anticoagulant therapies (2012-2013-2014)

Agewall Stefan A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Orion : Inotropi (2012)

- Pfizer : Lipids (2012-2013)

- Sanofi Aventis : Lipids (2012-2013)

- Siemens Healthcare : Markers (2012-2013)

- Astra Zeneca : Platelet inhibition (2012-2013-2014)

- Böhringer Ingelheim : Anticoagulatn treatment (2013)

- Roche Diagnostics : Cardiac markers (2013)

- Orion : Heart failure (2013)

Andreassen Arne Kristian A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- United Therapeutics : Remodulin / Pulmonary arterial hypertension (2012-2013-2014)

Androulakis Aristides None declared (2012-2013-2014)

Anguita Sanchez Manuel P A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Almirall Spain : Anticoagulants (2012-2013-2014)

22/08/2014

Guidelines on Acute PE 2014 (TF03) - Document Reviewers



of 43

Anguita Sanchez Manuel P - Bayer : Anticoagulation (2012-2013-2014)

- Boehringer-Ingelheim : Anticoagulation (2012-2013-2014)

- Bristol Myers Squibb : Anticoagulation (2012-2013-2014)

- Astra Zeneca : Antiplatelet drugs (2012-2013-2014)

- Servier : Heart failure (2012-2013-2014)

- Pfizer : Heart failure; Anticoagulation (2012-2013-2014)

- Daiichi Sankyo : Hypertension (2012-2013-2014)

Asanin Milika None declared (2012-2013-2014)

Asteggiano Riccardo None declared (2012-2014)

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Chiesi Pharma : Rosuvastatin (2013)

Barakovic Fahir None declared (2012-2013-2014)

Bauersachs Rupert A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Bristol Myers Squibb : Apixaban (2012-2013-2014)


- Daiichi Sankyo : Edoxaban (2012-2013-2014)

- Sanofi Aventis : Enoxaparin (2012-2013-2014)

- Bayer Healthcare : Rivaroxaban (2012-2013-2014)

Becattini Cecilia A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Boehringer-Ingelheim : Antithrombotic drugs (2012-2013-2014)

- Bayer Healthcare : Antithrombotic drugs (2012-2013-2014)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Bayer Healthcare : Antithrombotic drugs (2012-2013-2014)

Bounameaux Henri A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Daiichi Sankyo : anticoagulants (2012-2013-2014)

22/08/2014




of 43

Bounameaux Henri - Pfizer : anticoagulants (2012-2013-2014)

- Sanofi Aventis : anticoagulants (2012-2013-2014)

- Bayer Healthcare : anticoagulants (2012-2013-2014)

- Thrombosis Research Institute, London : Member of Steering committee/National coordinator Council of GARFIELD Registry (2013)

D - Research funding (departmental or institutional).- Daiichi Sankyo : anticoagulants (2012-2013)

- Bayer Healthcare : anticoagulants (2013-2014)

Buller Harry A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Thrombogenics : anticoagulation (2012)

- Boehringer-Ingelheim : anticoagulation (2012-2013-2014)

- Daiichi Sankyo : anticoagulation (2012-2013-2014)

- Pfizer : anticoagulation (2012-2013-2014)

- Bayer Healthcare : anticoagulation (2012-2013-2014)

- Bristol Myers Squibb : anticoagulation (2012-2013-2014)

- Isis Pharmaceuticals : anticoagulation (2012-2013-2014)

D - Research funding (departmental or institutional).- Bayer Healthcare : anticoagulation (2012)

- Pfizer : anticoagulation (2012-2013-2014)

- Daiichi Sankyo : Anticoagulation (2013-2014)

Christersson Christina A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- CSL Behring : Bleeding coagulation speakers fees (2012-2013-2014)

- Bristol Myers Squibb : new oral anticoagulant speakers fees, ARISTOTLE Investigator (2012-2013-2014)

- Boehringer-Ingelheim : REDEEM, REALIGN Investigator (2012-2013-2014)

Chukhrukidze Archil None declared (2012-2013-2014)

22/08/2014




of 43

Davos Constantinos None declared (2014)

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Merck Sharp & Dohme : Cardiovascular (2012)

- Servier : Heart Failure (2012-2013)

- PharmaSwiss : Hypertension (2012-2013)

- Astra Zeneca : Cardiovascular (2013)

De Pauw Michel A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Actelion : Pulmonary Hypertension (2012-2013)

- Actelion, Pfizer : Pulmonary Hypertension (2014)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Bayer : Pulmonary Hypertension (2012-2013)

D - Research funding (departmental or institutional).- Pfizer : Pulmonary Hypertension (2012-2013)

Deaton M Christi None declared (2013-2014)

D - Research funding (departmental or institutional).- Novo-Nordisk : patients with heart failure and diabetes (2012)

Dzemeshkevich Sergei None declared (2012-2013-2014)

Elmet Mart None declared (2012-2013-2014)

Ereminiene Egle None declared (2012-2013-2014)

Erol Cetin A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Servier : Hypertension (2013-2014)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Servier : Perindopril (2012)

- Menarini : Trandolapril (2012)

- Menarini : Hypertension (2013-2014)

C - Receipt of royalties for intellectual property.- Astra Zeneca : Ticagrelor (2012)

22/08/2014




of 43

Fedele Francesco None declared (2012-2013-2014)

Ferreira Daniel A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Bayer : rivaroxaban (2012)


Forster Tamas A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Egis Pharma : Hypertension (2012-2013-2014)

- Pfizer : NOAC (2012-2013-2014)

- Bayer Healthcare : NOAC (2012-2013-2014)

- Actelion : PAH (2012-2013-2014)

- Boehringer-Ingelheim : NOAC (2013-2014)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Terumo Inc : transradial cath (2012-2013-2014)

Geersing Geert-Jan A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Daiichi Sankyo : NOAC's (2013-2014)

D - Research funding (departmental or institutional).- Bayer Healthcare : NOAC's (2012-2013-2014)

Gomez Sanchez Miguel Angel

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- GlaxoSmithKline : ambrisentan, tadalafil (2012)

- Ferrer Internacional : treprostinil (2012-2013)

- Servier : ivabradine (2012-2013-2014)

- Actelion : macitentan (2012-2013-2014)

- Bayer Schering Pharma : riociguat (2012-2013-2014)

- GlaxoSmithKline : ambrisentan (2014)

Hansen Morten Lock A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Boehringer-Ingelheim : Antithrombotics (2012-2013)

- Pfizer : Antithrombotics (2012-2013)

22/08/2014




of 43

Hansen Morten Lock - Bristol Myers Squibb : Antithrombotics (2012-2013)

- Bristol Myers Squibb : Apixaban (2014)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Boehringer-Ingelheim : Dabigatran (2014)

D - Research funding (departmental or institutional).- Bristol Myers Squibb : Antithrombotics (2012-2013)

Harjola Veli-Pekka A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Bayer : Xarelto (2012)

- Novartis : Acute heart failure (2013)

- Bayer : Antithrombotic drugs (2013)

- Boehringer-Ingelheim : Antithrombotic drugs (2013)

- Pfizer : Antithrombotic drugs (2013)

- Resmed : Sleep apnea (2013)

- Boehringer-Ingelheim : cardiology (2014)

- Pfizer : cardiology (2014)

- Bayer AG : cardiology (2014)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Pfizer : Apixaban (2012)

- Bayer : Acute heart failure (2013)

- Novartis : Acute heart failure (2013)

- Resmed : Chronic heart failure (2013)

C - Receipt of royalties for intellectual property.- Orion : levosimendan (2012)

D - Research funding (departmental or institutional).- Roche Diagnostics : biomarkers (2012)

- Orion : Acute heart failure (2014)

22/08/2014




of 43

Harjola Veli-Pekka - Novartis : critical care (2014)

- Servier : heart failure (2014)

E - Research funding (personal).- Resmed : sleep apnea (2012)

Hendriks Jeroen None declared (2012-2013-2014)

Hoes Arno B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Boehringer-Ingelheim : Member Scientific Committee of Zorro; a research program sponsored by an unrestricted grant from

Boehringer-Ingelheim with the aim to improve anticoagulant care in the Netherlands (2012)

- Various : I chair a large (around 500 employees) research and teaching institute within our University Medical Center. We perform both investigator- and industry-driven research projects with a number of pharmaceutical and diagnostic companies. In addition, some of my members of staff receive unrestricted grants for research projects from a number of companies. It is our explicit policy to work with several companies and not to focus on one or two industrial partners. I receive no personal payment from any industrial partner. (2012-2013-2014)

- Zorg binnen Bereik : Member of project team of Zorg Binnen Bereik, a Dutch Achmea (health insurance company) and Philips sponsored research program to test patient e-health platforms in patients with chronic disease (heart failure, COPD and diabetes) (2012-2013-2014)

D - Research funding (departmental or institutional).- I am the director of a large (around 500 employees) research and teaching institute within our University Medical Center. We

perform both investigator- and industry-driven research projects with a number of pharmaceutical and diagnostic companies. In addi : I chair a large (around 500 employees) research and teaching institute within our University Medical Center. We perform both investigator- and industry-driven research projects with a number of pharmaceutical and diagnostic companies. In addition, some of my members of staff receive unrestricted grants for research projects from a number of companies. It is our explicit policy to work with several companies and not to focus on one or two industrial partners. I receive no personal payment from any industrial partner. (2012-2013-2014)

Jimenez David A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Boehringer-Ingelheim : Thrombosis (2012-2013)

- Daiichi Sankyo : Thrombosis (2012-2013)

- Sanofi Aventis : Thrombosis (2012-2013)

- Bayer Healthcare : Thrombosis (2012-2013)

- Bristol Myers Squibb : Thrombosis (2012-2013)

22/08/2014




of 43

Jimenez David - Rovi : Thrombosis (2012-2013)

- Leo Pharma : Thrombosis (2012-2013)

- Boehringer-Ingelheim : Anticoagulation (2014)

- Daiichi Sankyo : Anticoagulation (2014)

- Sanofi Aventis : Anticoagulation (2014)

- Bayer Healthcare : Anticoagulation (2014)

- Bristol Myers Squibb : Anticoagulation (2014)

- Rovi : Anticoagulation (2014)

- Leo Pharma : Anticoagulation (2014)

D - Research funding (departmental or institutional).- Sanofi Aventis : Thrombosis (2012-2013)

- Rovi : Thrombosis (2012-2013)

E - Research funding (personal).- Sanofi Aventis : Anticoagulation (2014)

Kilickap Mustafa None declared (2012-2013-2014)

Kostova Nela None declared (2013-2014)

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Alcaloid AD Skopje : dyslipidemia ant arterial hypertension (2012)

Kurzyna Marcin A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Actelion : pulmonary hypertension (2012-2013-2014)

- GlaxoSmithKline : pulmonary hypertension (2012-2013-2014)

- AOP Orphan Pharmaceuticals : pulmonary hypertension (2012-2013-2014)

- Bayer Healthcare : pulmonary hypertension, thrombosis (2012-2013-2014)

- Pfizer : pumonary hypertension (2012-2013-2014)

22/08/2014




of 43

Kurzyna Marcin - Sanofi Aventis : thrombosis (2012-2013-2014)

D - Research funding (departmental or institutional).- Sanofi Aventis : thrombosis (2012-2013-2014)

Maca Aija None declared (2012)

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Bayer AG : Therapeutic area (2013)

- Bayer AG , Astra Zeneca : Therapeutic area (2014)

Mareev Viatcheslav A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Abbott : cardiology (2012-2013-2014)

- Astra Zeneca : cardiology (2012-2013-2014)

- Novartis : cardiology (2012-2013-2014)

- Pfizer : cardiology (2012-2013-2014)

- Servier : cardiology (2012-2013-2014)

- Sanofi Aventis : cardiology (2012-2013-2014)

- Berlin Chemie AG : cardiology (2012-2013-2014)

- Takeda Pharmaceuticals : cardiology (2012-2013-2014)

- Krka Pharma : cardiology (2012-2013-2014)

Meyer Guy A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Leo Pharma : Anticoagulants (2012-2013)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Daiichi Sankyo : Anticoagulants (2012-2013)

- Bayer Healthcare : Anticoagulants (2012-2013)

- Sanofi Aventis : Anticoagulants (2013)

- Bayer : Anticoagulants (2014)

D - Research funding (departmental or institutional).- Boehringer-Ingelheim : Thrombolytics (2012-2013)

22/08/2014




of 43

Meyer Guy - Leo Pharma : Anticoagulants (2012-2013-2014)

Micallef Josef None declared (2013-2014)

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astra Zeneca : speaker fee: one lecture (2012)

Monreal Bosch Manuel A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Bayer AG : Rivaroxaban (2012)

- Daiichi Sankyo : Edoxaban (2012-2013-2014)

- Pfizer : Eliquis (2013)

- Bayer Schering Pharma, : Xarelto (2013)

- Sanofi Aventis : Clexane (2014)

- Bayer AG : Xarelto (2014)

D - Research funding (departmental or institutional).- Bayer AG : Rivaroxaban (2012)

- Sanofi Aventis : Clexane (2012-2013-2014)

- Bayer AG : Xarelto (2013-2014)

Morais Joao A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Pfizer : anticoagulants (2012)

- JaBA Recordati : Hypertension (2012)

- Boehringer-Ingelheim : anticoagulants (2012-2014)

- Bayer Healthcare : anticoagulants (2012-2014)

- Astra Zeneca : antiplatelets (2012-2014)

- JaBA Recordati : Lipids and Hypertension (2013)

- Merck Sharp & Dohme : Lpids (2013)

- Bayer Healthcare : Rivaroxaban (2013)

22/08/2014




of 43

Morais Joao - Astra Zeneca : Ticagrelor (2013)

- Daiichi Sankyo : anticoagulants (2014)

- Merck Sharp & Dohme : lipids (2014)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- TIMI group : anticoagulants (2012)

- Duke Research Unit : antiplatelets (2012)

E - Research funding (personal).- Servier : ischemic heart disease (2012-2014)

- Servier : ivabradin (2013)

Najafov Ruslan None declared (2012-2013-2014)

Nihoyannopoulos Petros None declared (2012)

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- GSK : Consultant for Imaging studies (2013-2014)

Parkhomenko Alexander A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Servier : ivabradin, trimetazidin (2012)

- Servier : trimetazidin, rivaroxaban, ticagrelor (2013)

- Boehringer-Ingelheim : dabigatran (2014)

- Astra Zeneca : ticagrelor (2014)

- Servier : trimetazidin, ivabradin (2014)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Bayer : rivaroxabane (2012-2013-2014)

C - Receipt of royalties for intellectual property.- BHFZ : corvitine (2012-2013-2014)

Pepke-Zaba Joanna A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Bayer : speaker fees , consultancy, advisory board fees (2012-2013-2014)

- Actelion : speaker fees , consultancy, advisory board fees (2012-2013-2014)

22/08/2014




of 43

Pepke-Zaba Joanna B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- GlaxoSmithKline : Advisory Board, educational grant (2012)

- Actelion : speaker fees, consultancy, (2012)

- Bayer : speaker fees, consultancy, Advisory Board, educational grant (2012)

- GlaxoSmithKline : educational grant, travelling grants (2013-2014)

- Bayer : unrestricted educational grant, , travelling grants (2013-2014)

- Actelion : travelling grants , unrestricted educational grants, (2013-2014)

D - Research funding (departmental or institutional).- Actelion : educational grant for department (2012-2013-2014)

E - Research funding (personal).- Bayer : research for department (2012)

- Bayer : unrestricted research grant for department (2013-2014)

Petris Antoniu Octavian A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astra Zeneca : Atacand (2012)

- Astra Zeneca : Axanum (2012)

- Sanofi Aventis : cardiovascular disease management (2012)

- Abbott Laboratories : Omacor (2012)

- Pfizer : Sortis (2012)

- Actavis : Telmisartan Actavis (2012)

- Servier : heart failure cases presentation (2012-2013)

- Servier : hypertension (2012-2013)

- SC Astra Zeneca Pharma SRL : Atacand (2013)

- SC Astra Zeneca Pharma SRL : Axanum (2013)

- SC Astra Zeneca Pharma SRL : Brilique (ticagrelor) in acute coronary syndrome (2013)

22/08/2014




of 43

Petris Antoniu Octavian - PSI CRO AG & Boehringer Ingelheim Pharma GmbH Co : Gloria-AF Registry Program - investigator (2013)

- Sandoz Pharma Services SRL : Metoprolol (2013)

- SC Pfizer Romania SRL : Norvasc (amlodipine) (2013)

- Actavis SRL : sponsorship Heart Failure Congress (2013)

- Sc Alfa Wassermann SRL : suledoxidum (2013)

- SC Servier Pharma SRL : Investigator - study involving Tenaxum ( Rilmenidine ) (2014)

- Astra Zeneca : Speaker fee: Case report - Romanian Society of Cardiology course (2014)

- Sanofi Aventis : Speaker fee: Case report - XIV Conference on Atherothrombosis (2014)

- Astra Zeneca : Speaker fee: Crestor (rosuvastatine) (2014)

- SC Servier Pharma SRL : Speaker fee: Prestance for hypertension - The value of fixed combinations (2014)

Popescu Bogdan Alexandru A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- GE Healthcare : Imaging (2012-2013-2014)

- Chimimportexport Plurimex : Antihypertensive drugs (2013-2014)

Rokyta Richard A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- AOP Orphan Pharmaceuticals : esmolol (2012-2013)

- Novartis : acute heart failure (2012-2013-2014)

- Astra Zeneca : Brilique (2012-2013-2014)

- AOP Orphan Pharmaceuticals : esmolol, vernakalant (2014)

D - Research funding (departmental or institutional).- Institutional research fund, Ministry of Health, Czech Republic : cardiovascular medicine (2012-2013-2014)

- Charles University Research Fund : cardiovascular medicine (2012-2013-2014)

Rosenkranz Stephan A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Pfizer : Pulmonary Hypertension (2012)

- Lilly : Pulmonary Hypertension (2012)

22/08/2014




of 43

Rosenkranz Stephan - Actelion : Pulmonary Hypertension (2012-2013-2014)

- GlaxoSmithKline : Pulmonary Hypertension (2012-2013-2014)

- United Therapeutics : Pulmonary Hypertension (2012-2013-2014)

- Novartis : Pulmonary Hypertension, Heart Failure (2012-2013-2014)

- Bayer : Pulmonary Hypertension, Heart Failure, Anticoagulants (2012-2013-2014)

- Pfizer : Pulmonary Hypertension, Anticoagulants (2013-2014)

D - Research funding (departmental or institutional).- Novartis : Pulmonary Hypertension (2012)

- Bayer : Pulmonary Hypertension (2012-2013-2014)

- Actelion : Pulmonary Hypertension (2012-2013-2014)

- United Therapeutics : Pulmonary Hypertension (2012-2013-2014)

- AOP Orphan Pharmaceuticals : Pulmonary Hypertension (2013-2014)

- Novartis : Pulmonary Hypertension, Heart Failure (2013-2014)

Sade Leyla Elif None declared (2012-2013-2014)

Sanchez Olivier A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- GlaxoSmithKline : ambrisentan (2012-2013)

- Actelion : bosentan (2012-2013)


- Boehringer-Ingelheim : tiotropium (2012-2013)

- Bayer : rivaroxaban (2012-2013-2014)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Daiichi Sankyo : edoxaban (2012-2013-2014)


- Portola Pharmaceuticals : betrixaban (2013-2014)

22/08/2014




of 43

Simkova Iveta A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Boehringer-Ingelheim : dabigatran (2012)

- Pfizer : eplerenon, sildenafil (2012)

- GlaxoSmithKline : ambrisentan (2012-2013-2014)

- Servier : arterial hypertension (2012-2013-2014)

- Merck Serono : bisoprolol (2012-2013-2014)

- Actelion : bosentan (2012-2013-2014)


- AOP Orphan Pharmaceuticals : treprostinil (2012-2013-2014)

- Pfizer : eplerenon, sildenafil, apixaban (2013-2014)

Skoric Bosko A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Berlin Chemie AG : Nebilet (2012)

- Abbott : Omacor (2012)

- Astra Zeneca : ticagrelor (2012)

- Abbott : Prograf (2013)

- Astra Zeneca : Ranexa (2013)

- Berlin Chemie AG : Ranexa (2013-2014)

- Servier : Corlentor (2014)

- Astellas : Prograf (2014)

D - Research funding (departmental or institutional).- Ministry of Science, Education and Sport of the Republic of Croatia : platelet function testing (2012-2013-2014)

Skoro-Sajer Nika A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Pfizer : treatment of pulmonary hypertension (2012-2013-2014)

- Actelion : treatment of pulmonary hypertension (2012-2013-2014)

22/08/2014




of 43

Skoro-Sajer Nika - GlaxoSmithKline : treatment of pulmonary hypertension (2012-2013-2014)

- United Therapeutics : treatment of pulmonary hypertension (2012-2013-2014)

- Bayer Schering Pharma : treatment of pulmonary hypertension (2012-2013-2014)

- AOP Orphan Pharmaceuticals : treatment of pulmonary hypertension (2012-2013-2014)

C - Receipt of royalties for intellectual property.- UT Therapeutics : pulmonary hypertension (2012-2013-2014)

Sooronbaev Talant None declared (2012-2013-2014)

Spyropoulos Alex A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Bristol Myers Squibb : apixaban (2012-2013-2014)

- Boehringer-Ingelheim : dabaigatran (2012-2013-2014)

- Daiichi Sankyo : edoxaban (2012-2013-2014)

- Sanofi Aventis : lovenox (2012-2013-2014)


- Janssen-Cilag : rivaroxaban (2012-2013-2014)

Sudzhaeva Svetlana None declared (2012-2013-2014)

Tokmakova Mariya A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astra Zeneca : ACS, prevention (2012-2013-2014)

- Bayer : atrial fibrillation (2012-2013-2014)

- Boehringer-Ingelheim : atrial fibrillation (2012-2013-2014)

- Pfizer : atrial fibrillation, prevention (2012-2013-2014)

- Sanofi Aventis : CAD, prevention (2012-2013-2014)

- Servier : Heart failure, CAD, hypertension (2012-2013-2014)

- Novartis : hypertension, heart failure (2012-2013-2014)

22/08/2014




of 43

Tokmakova Mariya - Berlin Chemie AG : Myocardial infarction, hypertension, heart failure (2012-2013-2014)

22/08/2014




of 43

Achenbach Stephan A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Siemens Healthcare : CT (2012-2013)

- Servier : Imaging (2012-2013)

- Guerbet : Imaging (2012-2013)

- Bayer : Anticoagulation (2013)

- Behring : Anticoagulation (2013)

- Astra Zeneca : Antiplatelet Therapy (2013)

- Abbott : Coronary Intervention (2013)

D - Research funding (departmental or institutional).- Abbott : Coronary Intervention (2013-2014)

- Siemens Healthcare : Imaging (2013-2014)

Baumgartner Helmut A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Actelion : Bosentan for PAH treatment in congenital heart disease (2012)

- Edwards Lifesciences : transcatheter valve implantation (2012-2013-2014)

- Actelion : Bosentan and Macicentan for PAH treatment in congenital heart disease (2013-2014)

- St. Jude Medical : Occluders for shunt closure (ASD, PFO, PDA, VSD) (2013-2014)

- Abbott : transcather mitral valve repair (Mitraclip) (2013-2014)

- Direct Flow Medical : transcatheter valve implantation (2013-2014)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Actelion : Bosentan for PAH treatment in congenital heart disease (2012-2013-2014)

- Edwards Lifesciences : transcatheter valve implantation (2012-2013-2014)

- St. Jude Medical : Occluders for shunt closure (ASD, PFO, PDA, VSD) (2013-2014)

- Abbott : transcather mitral valve repair (Mitraclip) (2013-2014)

- Direct Flow Medical : transcatheter valve implantation (2013-2014)

29/07/2014

Committee for Practice Guidelines 2012-2014



of 43

Bax Jeroen D - Research funding (departmental or institutional).- Servier : Farma (2012-2013-2014)

- Edwards Lifesciences : Heart Valves (2012-2013-2014)

- GE Healthcare : Imaging (2012-2013-2014)

- Lantheus Inc : Imaging (2012-2013-2014)

- Boston Scientific : Pacing (2012-2013-2014)

- Medtronic : Pacing (2012-2013-2014)

- St Jude Medical : Pacing (2012-2013-2014)

- Biotronik : Pacing (2012-2013-2014)

Bueno Hector A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Novartis : Heart Failure and elinogrel (2012)

- Bayer Healthcare : Aspirin, rivaroxaban (2012-2013-2014)

- Roche Pharma : Dalcetrapib (2012-2013-2014)

- Daiichi Sankyo : Prasugrel (2012-2013-2014)

- Eli Lilly : Prasugrel (2012-2013-2014)

- Astra Zeneca : Ticagrelor (2012-2013-2014)

- BMS/Pfizer : Apixaban (2013)

- Novartis : Relaxin (2013)

- Sanofi Aventis : Clopidogrel (2013-2014)

- Pfizer : Apixaban (2014)

- Bristol Myers Squibb : Apixaban (2014)

- Menarini : Ranolazine (2014)

- Novartis : Serelaxin (2014)

29/07/2014




of 43

Bueno Hector E - Research funding (personal).- Astra Zeneca : Ticagrelor (2012-2013-2014)

Deaton M Christi None declared (2013-2014)

D - Research funding (departmental or institutional).- Novo-Nordisk : patients with heart failure and diabetes (2012)

Erol Cetin A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Servier : Hypertension (2013-2014)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Servier : Perindopril (2012)

- Menarini : Trandolapril (2012)

- Menarini : Hypertension (2013-2014)

C - Receipt of royalties for intellectual property.- Astra Zeneca : Ticagrelor (2012)

Fagard Robert None declared (2012-2013-2014)

Ferrari Roberto A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Boehringer-Ingelheim : Anticoaguland and diabetes. Dagabitran (2012)

- Medical Trials Analysis : Consultant in Clinical Trials (2012)

- Servier : Myocardial ischamia and heart failure. Perindopril, ivabradine, alodipine, trimetazidine (2012)

- Novartis : Acute heart failure. Saralaxine (2013-2014)

- Boehringer-Ingelheim : Anticoagulants and diabetes. Dagabitran (2013-2014)

- Medical Trials Analysis : Consultant in clinical trials - expertise (2013-2014)

- Merk Serono : Coronary artery disease, heart failure, beta blockers (2013-2014)

- Servier : Myocardial ischemia and heart failure. Perindopril, Ivabradine, Amlodipine, Trimetazedine (2013-2014)

D - Research funding (departmental or institutional).- Fondazione Salvatore Maugeri : General (2012)

- Schering-Plough : Anti-platelet agent TRACER (2012-2013-2014)

29/07/2014




of 43

Ferrari Roberto - Servier : Perindopril, ivabradine, amlodipine CLARifY and SIGNifY (2012-2013-2014)

Hasdai David A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Boehringer-Ingelheim : Pradaxa (2012-2013-2014)

- Bayer : Rivaroxiban (2012-2013-2014)

- Astra Zeneca : Ticagrelor (2012-2013-2014)

Hoes Arno B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Boehringer-Ingelheim : Member Scientific Committee of Zorro; a research program sponsored by an unrestricted grant from

Boehringer-Ingelheim with the aim to improve anticoagulant care in the Netherlands (2012)

- Various : I chair a large (around 500 employees) research and teaching institute within our University Medical Center. We perform both investigator- and industry-driven research projects with a number of pharmaceutical and diagnostic companies. In addition, some of my members of staff receive unrestricted grants for research projects from a number of companies. It is our explicit policy to work with several companies and not to focus on one or two industrial partners. I receive no personal payment from any industrial partner. (2012-2013-2014)

- Zorg binnen Bereik : Member of project team of Zorg Binnen Bereik, a Dutch Achmea (health insurance company) and Philips sponsored research program to test patient e-health platforms in patients with chronic disease (heart failure, COPD and diabetes) (2012-2013-2014)

D - Research funding (departmental or institutional).- I am the director of a large (around 500 employees) research and teaching institute within our University Medical Center. We

perform both investigator- and industry-driven research projects with a number of pharmaceutical and diagnostic companies. In addi : I chair a large (around 500 employees) research and teaching institute within our University Medical Center. We perform both investigator- and industry-driven research projects with a number of pharmaceutical and diagnostic companies. In addition, some of my members of staff receive unrestricted grants for research projects from a number of companies. It is our explicit policy to work with several companies and not to focus on one or two industrial partners. I receive no personal payment from any industrial partner. (2012-2013-2014)

Kirchhof Paulus A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Boehringer-Ingelheim : cardiovascular (2012-2013-2014)

- Daiichi Sankyo : cardiovascular (2012-2013-2014)

- Medtronic : cardiovascular (2012-2013-2014)

- Pfizer : cardiovascular (2012-2013-2014)

- St Jude Medical : cardiovascular (2012-2013-2014)

29/07/2014




of 43

Kirchhof Paulus - Sanofi Aventis : cardiovascular (2012-2013-2014)

- Meda pharma : cardiovascular (2012-2013-2014)

- Bristol Myers Squibb : cardiovascular (2012-2013-2014)

- Merck Sharp & Dohme : cardiovascular (2012-2013-2014)

- Otsuka Pharmaceuticals Development and Commercialization (consultancy) : cardiovascular (2012-2013-2014)

- Johnson & Johnson : cardiovascular (2014)

- Bayer Healthcare : cardivoascular (2014)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Portola Pharmaceuticals : cardiovascular (2012)

- Boehringer-Ingelheim : cardiovascular (2012-2013-2014)

- Bayer Healthcare : cardiovascular (2012-2013-2014)

- BMS / Pfizer alliance : cardiovascular (2012-2013-2014)

- Gilead : cardiovascular (2013)

- Daiichi Sankyo : cardiovascular (2014)

D - Research funding (departmental or institutional).- St Jude Medical : cardiovascular (2012-2013)

- Sanofi Aventis : cardiovascular (2012-2013)

- Meda pharma : cardiovascular (2012-2013-2014)

- British Heart Foundation : cardiovascular (2014)

- European Union (FP7) : cardiovascular (2014)

- Daiichi Sankyo : cardiovascular (IIT grant to AFNET) (2014)

- St Jude Medical : cardiovascular (IIT grant to AFNET) (2014)

- Sanofi Aventis : cardiovascular (IIT grant to AFNET) (2014)

29/07/2014




of 43

Kirchhof Paulus - BMS/Pfizer : cardiovascular (IIT grant to AFNET) (2014)

- Fondation Leducq : cardiovascular (starting in October 2014) (2014)

- German Ministry of Education and Research (BMBF) : cardivoascular (to AFNET) (2014)

Knuuti Juhani A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Lantheus Inc : Perfusion imaging tracer development (2012-2013-2014)

D - Research funding (departmental or institutional).- Servier : Vascular inflammation (2012-2013-2014)

- Athera : vascular inflammation (2012-2013-2014)

- Orion Pharma : Heart failure drug research (2014)

Kolh Philippe H A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Regado Biosciences : Antithrombotic agents (2012)

- Astra Zeneca : Antiplatelet agents (2012-2013-2014)

- B.Braun : Surgical instruments (2013-2014)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Merck Sharp & Dohme : Antistaphylococcic vaccine (2012)

D - Research funding (departmental or institutional).- St Jude Medical : Cardiac valves (2012-2013)

- Boston Scientific : Coronary stents (2012-2013)

- Siemens Healthcare : Medical imaging (2012-2013)

- Johnson & Johnson : Thoracoscopic devices (2012-2013)

- Edwards Lifesciences : Cardiac valves (2012-2013-2014)

- Medtronic : Cardiac valves (2012-2013-2014)

Lancellotti Patrizio A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Boston Scientific : Heart Failure (2012)

- Servier : Heart Failure (2013)

- Abbott : MitraClip (2013)

29/07/2014




of 43

Lancellotti Patrizio - Menarini : nebivolol (2014)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astra Zeneca : Brilique (2012)

- Servier : Coversyl (2012)

- Abbott Vascular : MitraClip (2012)

- Astrazeneca : Dyslipidemia (2013)

- Boston Scientific : CRT (2014)

- Servier : procoralan (2014)

D - Research funding (departmental or institutional).- Actelion : Pulmonary Hypertension (2013)

Linhart Ales A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Servier : Arterial hypertension (2012-2013-2014)

- Boehringer-Ingelheim : Arterial hypertension, atrial fibrillation (2012-2013-2014)

- GlaxoSmithKline : Atherosclerosis (2012-2013-2014)

- Merck Sharp & Dohme : Dyslipidemia (2012-2013-2014)

- Bayer Schering Pharma : Dyslipidemia, pulmonary hypertension, atrial fibrillation (2012-2013-2014)

- Shire HGT : Fabry disease (2012-2013-2014)

- Genzyme : Fabry disease (2012-2013-2014)

- Actelion : Pulmonary hypertension (2012-2013-2014)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Shire HGT : Fabry disease (2012)

D - Research funding (departmental or institutional).- Shire HGT : Fabry disease (2014)

Nihoyannopoulos Petros None declared (2012)

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- GSK : Consultant for Imaging studies (2013-2014)

29/07/2014




of 43

Piepoli Massimo Francesco None declared (2013-2014)

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Chiesi Pharma : Anti-dyslipidemic therapy (2012)

Ponikowski Piotr A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Amgen : heart failure (2012)

- Cothera : heart failure (2012)

- Coridea : heart failure (2012)

- Boehringer-Ingelheim : anticoagulant (2012-2013-2014)

- Bristol Myers Squibb : anticoagulant (2012-2013-2014)

- Respicardia : anticoagulant (2012-2013-2014)

- Abbott Vascular : devices (2012-2013-2014)

- Novartis : heart failure (2012-2013-2014)

- Johnson & Johnson : heart failure (2012-2013-2014)

- Bayer Healthcare : heart failure (2012-2013-2014)

- Vifor Pharma ltd : heart failure (2012-2013-2014)

- Pfizer : heart failure, anticoagulant (2012-2013-2014)

- Servier : heart failure, coronary artery disease (2012-2013-2014)

- Bayer : anticoagulant (2013-2014)

- ROSCHE : diabetes (2013-2014)

- Cardiorentis : heart failure (2013-2014)

- CIBIEM : heart failure (2013-2014)

- Amgen : heart failure, lipids (2013-2014)

D - Research funding (departmental or institutional).- Vifor Pharma ltd : heart failure (2012-2013-2014)

29/07/2014




of 43

Sirnes Per Anton B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Quintiles on behalf of Novartis : Investig fee CANTOS study (2012)

- Merck Sharp & Dohme : Investigartor fee HPS2-THRIVE STUDY (2012)

- Boehringer-Ingelheim : Investigator Fee Relyable study (2012)

- Schering-Plough : Investigator fee TRA2P-TIMI50 study (2012)

- GlaxoSmithKline : Investig fee HZC113108 and LPL100601 studies (2012-2013)

- SticaresInterACt on behalf of Servier : Investig Fee SIGNIFY study (2012-2013)

- NORMA onbehalf of Janssen Cilar : Invest fee CANVAS study (2012-2013-2014)

- Amgen : Speeker fee (2013)

- Pfizer : speeker fee (2013)

- Quintiles on behalf Garfield AF Registry : Fee Garfield AF registry (2013-2014)

- Novartis : Investigatoprs fee CANTOS study (2013-2014)

Tamargo Juan Luis A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- sanodi-aventis : Dronedarone-antiarrhythmic agent (2012)

- Menarini : Ranolazina (2013)

- Menarini : Ranolazine (2014)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astra Zeneca (Unrestricted Grant) : Candesartan, Felodipine, Atenolol (2014)

D - Research funding (departmental or institutional).- Astra Zeneca : Unrestricted Grant (2013)

E - Research funding (personal).- Astra -Zeneca Foundation (NON-PROFIT FOUNDATION). two years Unrestricted Grant : None (2012)

- Instituto de Salud Carlos III. Ministerio de Economía y Competitividad. Gobierno de España : No product/device (2014)

Tendera Michal A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Bayer : Aspirin, Rivaroxaban (2012)

- Amgen : Darbopoietin (2012)

29/07/2014




of 43

Tendera Michal - Servier : Ivabradine, Phase II investigational products (2012)

- Amgen : Darbopoietine (2013)

- Bayer : Aspirin, Acarbose (2013-2014)

- Servier : Ivabradine (2013-2014)

- Janssen Cilag : Rivaroxaban (2014)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Servier : Ivabradine, Phase II investigational products (2012)

- Servier : Ivabradine (2014)

- Janssen-Cilag : Rivaroxaban (2014)

Torbicki Adam A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Cardiomems : implanted pulmonary artery pressure sensor (2012)

- United Therapeutics : Pulmonary arterial hypertension (2012)

- Lilly : pulmonary arterial hypertension - tadalafil (2012)

- AOP Orphan Pharmaceuticals : Pulmonary arterial hypertension - treprostinil (2012)

- Bristol Myers Squibb : thromboembolic disease - Apixaban (2012)

- GlaxoSmithKline : pulmonary arterial hypertension - ambrisentan (2012-2013)

- Actelion : pulmonary arterial hypertension - macitentan, selexipag (2012-2013-2014)

- Bayer Healthcare : pulmonary arterial hypertention - iloprost, riociguat, VTE - xarelto (2012-2013-2014)

- Bristol Myers Squibb : Pulmonary arterial hypertension (2013)

- Lilly : pulmonary arterial hypertension - ambrisentan (2013)

- Novartis : pulmonary hypertension (2014)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Sanofi Aventis : Thromboembolic disease (2012)

- Bayer Healthcare : Pulmonary hypertension (2012-2013-2014)

29/07/2014




of 43

Wijns William B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Tryton : device (2012)

- Astra Zeneca : pharma (2012)

- Biosensors : device (2012-2013-2014)

- Boston Scientific : device (2012-2013-2014)

- Edwards Lifesciences : device (2012-2013-2014)

- Medtronic : device (2012-2013-2014)

- St Jude Medical : device (2012-2013-2014)

- Biotronik : device (2012-2013-2014)

- Terumo Inc : device (2012-2013-2014)

- Abbott Vascular : device (2012-2013-2014)

- Cordis : device (2012-2013-2014)

- Orbus Nech : device (2012-2013-2014)

- MICELL : device (2012-2013-2014)

- Vessix : device (2012-2013-2014)

- GlaxoSmithKline : drug (2012-2013-2014)

D - Research funding (departmental or institutional).- Cardio3 Biosciences : cell therapy (2012-2013-2014)

- Boston Scientific : device (2012-2013-2014)

- Medtronic : device (2012-2013-2014)

- St Jude Medical : device (2012-2013-2014)

- Biotronik : device (2012-2013-2014)

- Abbott Laboratories : device (2012-2013-2014)

29/07/2014




of 43

Wijns William - MICELL : device (2012-2013-2014)

- Therabel : drug (2012-2013-2014)

Windecker Stephan A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Biosensors : Stent (2012)

- Boston Scientific : Stent (2012)

- Cordis : Stent (2012)

- Edwards Lifesciences : TAVI (2012)

- Astra Zeneca : Antiplatelet drug (2012-2013)

- Eli Lilly : Antiplatelet drug (2012-2013)

- Abbott : Stent (2012-2013)

- Medtronic : Stent (2012-2013)

- Biotronik : Stent (2012-2013)

D - Research funding (departmental or institutional).- Abbott : Stent (2012)

- Biosensors : Stent (2012)

- Medtronic : Stent (2012)

- Cordis : Stent (2012)

- St Jude Medical : OCT (2012-2013-2014)

- Biotronik : Stent (2012-2013-2014)


A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Abbott Vascular : Help in Design Echocardiographic protocol (2012)

- Merck Sharp & Dohme : Lecture (2012)

- Daiichii : Atrial Fib (2013)

- Merck Sharp & Dohme : Lipid Lowering (2013)

29/07/2014




of 43


- Philips : 3D echo (2014)

- MSD : CV risk factors (2014)

- Toshiba medical imaging : fusion imaging 3D echo CT (2014)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- European Research Foundation FP7 : CV Imaging (2012)

- European Research FP7 : CV Imaging (2013)

- Servier : Imaging in ISchemic patients (2013)

- Siemens Healthcare : 3d echo software and free style echo (2014)

C - Receipt of royalties for intellectual property.- Springer : ESC Textbook of CV Imaging (2012-2013)

D - Research funding (departmental or institutional).- Astra Zeneca : Clinical trial (2014)

- Ikaria : Clinical trial (2014)

29/07/2014




of 43

guidelines on acute pe 2014 (tf03) - tf members · 2015-01-29 · - stealth peptides : bendavia...

Documents